Changes in Inflammation, Oxidative Stress, Mitochondrial DNA Content after Rosiglitazone in HIV Lipoatrophy
OBJECTIVE: We aim to evaluate the mechanisms of rosiglitazone-induced fat recovery in HIV+ patients with lipoatrophy on thymidine Nucleoside Reverse Transcriptase Inhibitors (NRTI) sparing regimens. METHOD: Measures of limb fat (DXA), oxidative stress (F2 isoprostanes) and inflammation [High-sensiti...
Saved in:
Published in | Journal of AIDS & clinical research Vol. 3; no. 8; p. 174 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.01.2012
|
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVE: We aim to evaluate the mechanisms of rosiglitazone-induced fat recovery in HIV+ patients with lipoatrophy on thymidine Nucleoside Reverse Transcriptase Inhibitors (NRTI) sparing regimens. METHOD: Measures of limb fat (DXA), oxidative stress (F2 isoprostanes) and inflammation [High-sensitivity C-reactive protein (hsCRP), soluble Tumor Necrosis Factor Receptors (sTNFR)-I, sTNFR-II, and interleukin (IL)-6] were performed. Gluteal fat mitochondrial DNA (mtDNA) and peroxisome proliferator-activated receptor (PPAR)-γ RNA [expressed as PPAR-γ/Glyceraldehyde 6-Phosphate Dehydrogenase (GAPDH) RNA ratio] were measured by quantitative PCR. RESULT: 71 patients on thymidine NRTI-sparing regimens were randomized to rosiglitazone vs. placebo for 48 weeks. Duration off thymidine NRTIs was similar between groups. From week 0-48, limb fat increased significantly (p=0.02) more in the rosiglitazone than in the placebo group. Within both groups, F2-isoprostanes, sTNFR-I and sTNFR-II increased significantly (p ≤ 0.003), hsCRP decreased significantly (≤ 0.02), and IL-6 did not change. No differences were seen between groups in any of the inflammation markers. Fat mtDNA (copies/cell) increased nonsignificantly: +41(p=0.08) and +29(p=0.38) within rosiglitazone and placebo group; respectively. PPAR-γ/GAPDH ratio did not change within or between groups. CONCLUSION: Limb fat improvements seen after rosiglitazone were not associated with changes in mtDNA, oxidative or inflammation markers, or PPAR-γ expression. F2 isoprostanes and some of the inflammation markers worsened over time in these subjects on stable ART, regardless of the rosiglitazone assignment. Thus, lipoatrophy can be in part overcome by a separate pathway independent of mitochondrial DNA depletion, such as PPAR-γ. |
---|---|
AbstractList | OBJECTIVE: We aim to evaluate the mechanisms of rosiglitazone-induced fat recovery in HIV+ patients with lipoatrophy on thymidine Nucleoside Reverse Transcriptase Inhibitors (NRTI) sparing regimens. METHOD: Measures of limb fat (DXA), oxidative stress (F2 isoprostanes) and inflammation [High-sensitivity C-reactive protein (hsCRP), soluble Tumor Necrosis Factor Receptors (sTNFR)-I, sTNFR-II, and interleukin (IL)-6] were performed. Gluteal fat mitochondrial DNA (mtDNA) and peroxisome proliferator-activated receptor (PPAR)-γ RNA [expressed as PPAR-γ/Glyceraldehyde 6-Phosphate Dehydrogenase (GAPDH) RNA ratio] were measured by quantitative PCR. RESULT: 71 patients on thymidine NRTI-sparing regimens were randomized to rosiglitazone vs. placebo for 48 weeks. Duration off thymidine NRTIs was similar between groups. From week 0-48, limb fat increased significantly (p=0.02) more in the rosiglitazone than in the placebo group. Within both groups, F2-isoprostanes, sTNFR-I and sTNFR-II increased significantly (p ≤ 0.003), hsCRP decreased significantly (≤ 0.02), and IL-6 did not change. No differences were seen between groups in any of the inflammation markers. Fat mtDNA (copies/cell) increased nonsignificantly: +41(p=0.08) and +29(p=0.38) within rosiglitazone and placebo group; respectively. PPAR-γ/GAPDH ratio did not change within or between groups. CONCLUSION: Limb fat improvements seen after rosiglitazone were not associated with changes in mtDNA, oxidative or inflammation markers, or PPAR-γ expression. F2 isoprostanes and some of the inflammation markers worsened over time in these subjects on stable ART, regardless of the rosiglitazone assignment. Thus, lipoatrophy can be in part overcome by a separate pathway independent of mitochondrial DNA depletion, such as PPAR-γ. |
Author | Ross, Allison C El-Bejjani, Dalia Walker, Ulrich A Tungsiripat, Marisa Rizk, Nesrine McComsey, Grace A Storer, Norma Hu, Bo Lebrecht, Dirk Milne, Ginger |
AuthorAffiliation | 1 Cleveland Clinic, Cleveland, OH, USA 3 Albert-Ludwigs University, Freiburg, Germany 2 Case Western Reserve University, Cleveland, OH, USA 5 Vanderbilt University School of Medicine, Nashville, TN, USA 4 Department of Rheumatology, Basel, Switzerland |
AuthorAffiliation_xml | – name: 3 Albert-Ludwigs University, Freiburg, Germany – name: 2 Case Western Reserve University, Cleveland, OH, USA – name: 1 Cleveland Clinic, Cleveland, OH, USA – name: 4 Department of Rheumatology, Basel, Switzerland – name: 5 Vanderbilt University School of Medicine, Nashville, TN, USA |
Author_xml | – sequence: 1 givenname: Marisa surname: Tungsiripat fullname: Tungsiripat, Marisa organization: Cleveland Clinic, Cleveland, OH, USA – sequence: 2 givenname: Dalia surname: El-Bejjani fullname: El-Bejjani, Dalia – sequence: 3 givenname: Nesrine surname: Rizk fullname: Rizk, Nesrine – sequence: 4 givenname: Bo surname: Hu fullname: Hu, Bo – sequence: 5 givenname: Allison C surname: Ross fullname: Ross, Allison C – sequence: 6 givenname: Ulrich A surname: Walker fullname: Walker, Ulrich A – sequence: 7 givenname: Dirk surname: Lebrecht fullname: Lebrecht, Dirk – sequence: 8 givenname: Ginger surname: Milne fullname: Milne, Ginger – sequence: 9 givenname: Norma surname: Storer fullname: Storer, Norma – sequence: 10 givenname: Grace A surname: McComsey fullname: McComsey, Grace A |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23227444$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkUlPwzAQhS0EYv8BXJCPHFrwlji5IKGyVSogsV2taWK3hsQutouAX08qSgWnGc28efOkbwetO-80QgeUHAsq2QmjWdbPKeXHlBBCpVhD26vZ-p9-C-3H-NJpCC-LkrFNtMU4Y1IIsY1eB1NwEx2xdXjoTANtC8l618N3H7bu2neNH1LQMfbwjU2-mnpXBwsNPr89wwPvknYJg0k64Hsf7aSxCb66pAvD6-EzHtmZhxT8bPq5hzYMNFHvL-suerq8eBxc90d3V8PB2ahfcSpEn5VynBUaCgBuciEMaMNqYaSpZSmNHEsmpSikpBJ0TSrODCmrvCyYMSUhGd9Fpz--s_m41XXVJQzQqFmwLYRP5cGq_xtnp2ri3xXPaEZy3hkcLQ2Cf5vrmFRrY6WbBpz286howfIsK3IqOin9kVbBxxi0Wb2hRC04qQUHteCglpy6m8O_-VYXv1T4N6QOkGA |
CitedBy_id | crossref_primary_10_1016_j_biomag_2014_02_006 crossref_primary_10_1371_journal_pone_0170515 crossref_primary_10_7448_IAS_18_1_19033 |
ContentType | Journal Article |
Copyright | Copyright: © 2012 Tungsiripat M, et al. 2012 |
Copyright_xml | – notice: Copyright: © 2012 Tungsiripat M, et al. 2012 |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.4172/2155-6113.1000174 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2155-6113 |
EndPage | 174 |
ExternalDocumentID | 10_4172_2155_6113_1000174 23227444 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R21 AI060484 – fundername: NCRR NIH HHS grantid: UL1 RR024989 – fundername: NIAID NIH HHS grantid: K23 AI070078 – fundername: NIAID NIH HHS grantid: P30 AI036219 – fundername: NIAID NIH HHS grantid: R01 AI060484 – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: R01 AI060484 || AI |
GroupedDBID | 8TZ AAKDD ALMA_UNASSIGNED_HOLDINGS C~G DYU FRP GX1 KQ8 NPM OK1 AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c3144-297b58ea8aa3f644faef2d4f7fd797f7b7277487717aed0c32f09c6982ff90053 |
ISSN | 2155-6113 |
IngestDate | Tue Sep 17 21:09:57 EDT 2024 Fri Jun 28 15:22:35 EDT 2024 Fri Aug 23 01:04:35 EDT 2024 Sat Sep 28 08:36:26 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 8 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3144-297b58ea8aa3f644faef2d4f7fd797f7b7277487717aed0c32f09c6982ff90053 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doi.org/10.4172/2155-6113.1000174 |
PMID | 23227444 |
PQID | 1826558614 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3515063 proquest_miscellaneous_1826558614 crossref_primary_10_4172_2155_6113_1000174 pubmed_primary_23227444 |
PublicationCentury | 2000 |
PublicationDate | 20120101 |
PublicationDateYYYYMMDD | 2012-01-01 |
PublicationDate_xml | – month: 1 year: 2012 text: 20120101 day: 1 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of AIDS & clinical research |
PublicationTitleAlternate | J AIDS Clin Res |
PublicationYear | 2012 |
SSID | ssj0000398922 |
Score | 1.8943872 |
Snippet | OBJECTIVE: We aim to evaluate the mechanisms of rosiglitazone-induced fat recovery in HIV+ patients with lipoatrophy on thymidine Nucleoside Reverse... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 174 |
Title | Changes in Inflammation, Oxidative Stress, Mitochondrial DNA Content after Rosiglitazone in HIV Lipoatrophy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23227444 https://search.proquest.com/docview/1826558614 https://pubmed.ncbi.nlm.nih.gov/PMC3515063 |
Volume | 3 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKeOEFgfgqDGQkntAy0nw0ziPQTh0qnTRSqTxFTmNDxpRMTSpN_Qv4s7mzHZNsfRi8RK3d2tLdL-e7830Q8o6zPGBxsHbA7OIOvInSyZiUTiDCUPBglIUqQ-7rYjxbBl9W4Wow-N2JWto22fF6tzev5H-4CmPAV8yS_QfO2kVhAD4Df-EJHIbnnXisUwNUROtpKYG3Og8RyXZ2XeS6pvc3lQ2iQ-SbCqRdmatOHZMFZqRjBHtjOoWfV3XxA4t27ypdS2QGtuG8uKrQX96Wtd6jyJ5OtDPAZlmaCkLW05yARKmLDUZvm_ygorbHwfTS-SQuLnRvKUDhZWGnzoudbhEk6k3n_n-2Vaisuh4LFfrReiyUYAMtIwSTVeegHos9Y0Yy-x0Aso6UHenGPubANt9ungUBqGaY7tIujPEgrv1nt-724iw9Wc7naTJdJffIfSypiF0YJt-X1lvn-jGL1ZWUXU9fkeMuH27t0VdyblkuNwNwOxpN8og8NBykHzWuHpOBKJ-QXwZTtChpF1NH1CKKakQd0R6eKOCJGjxRhSfawxMuCHiiHTw9JcuTafJ55piGHM7aB8Pb8eIoC5ngjHNfgiItuZBeHshI5lEcySgDZTgCCzgaRVzk7tr3pBuvxzHzpIxR3D8jByXs-ILQsQRhEHgyjEFYuB5nLgdVN4_HGSjsmXCH5H1LwfRK111JwV5FcqdI7hTJnRpyD8nblsYpSEe88uKlqLZ1itZzGDLQQYfkuaa5XQ5sCSyPCTNRjxv2B1h5vT9TFj9VBXY_xMKc_ss77PuKPPj7DhySg2azFa9Bj22yNwpifwBemp0y |
link.rule.ids | 230,314,780,784,885,27924,27925 |
linkProvider | CAB International |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+Inflammation%2C+Oxidative+Stress%2C+Mitochondrial+DNA+Content+after+Rosiglitazone+in+HIV+Lipoatrophy&rft.jtitle=Journal+of+AIDS+%26+clinical+research&rft.au=Tungsiripat%2C+Marisa&rft.au=El-Bejjani%2C+Dalia&rft.au=Rizk%2C+Nesrine&rft.au=Hu%2C+Bo&rft.date=2012-01-01&rft.issn=2155-6113&rft.eissn=2155-6113&rft.volume=3&rft.issue=8&rft.spage=174&rft.epage=174&rft_id=info:doi/10.4172%2F2155-6113.1000174&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2155-6113&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2155-6113&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2155-6113&client=summon |